Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx) in oncology and inflammation.
Our lead asset, IMX-110, is currently in phase 1b/2a clinical trials for solid tumors in the United States and Australia. Our proprietary System Multi-Action RegulaTors SMAR xT Tissue-Specific Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times that of conventional medicines. Our TME Normalization Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. We have uncovered fundamental biological systems that link oncology and inflammation. Our pipeline includes pre-clinical tissue-specific biologics to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
ImmixBio was founded in 2012 by a visionary physician/entrepreneur, a world-renown pharmacology & drug delivery expert, a seasoned biotechnology patent attorney and an impact-driven founding family office. Achieving impactful patient outcomes is what guides Immix. The team are not just experts in their fields – they have also been personally touched by cancer. With this deeply personal impetus, ImmixBio’s objective is a qualitative response in each patient – nothing short. In memory of Donald E. Senn, Ph.D. who tragically lost his life to cancer at the height of a vibrant career as a biomedical scientist, and to all of the cancer patients and their families around the world who continue their brave fight.